首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lung Cancer

Lung Cancer杂志,由Elsevier Ireland Ltd出版,于1985年创刊,Monthly,出版语言English,ISSN:0169-5002,E-ISSN:1872-8332。

投稿咨询
Lung Cancer
Lung Cancer
Lung Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.3
CiteScore
7.4
期刊收录
SCI、SCIE

Lung Cancer(中文译名:《肺癌》),ISSN:0169-5002,EISSN:1872-8332,是Elsevier Ireland Ltd出版的国际性学术期刊,创刊于1985年,以Monthly形式稳定发行,2026年总发文量约320篇。该刊采用非OA开放访问,学科归属为医学 - 呼吸系统。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.3,2025年期刊CiteScore为7.4,2025年期刊自引率约3.8%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Lung Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-6周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,EnglandUSA、CHINA MAINLAND、Japan、Italy、France、GERMANY (FED REP GER)等为核心发文国家与地区;CHRISTIE NHS FOUNDATION TRUSTUNIVERSITY OF LONDON、UNIVERSITY OF MANCHESTER、ROYAL MARSDEN NHS FOUNDATION TRUST、UNICANCER、WYTHENSHAWE HOSPITAL NHS FOUNDATION TRUST、NATIONAL CANCER CENTER - JAPAN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 80 / 333

76.1

学科:RESPIRATORY SYSTEM SCIE Q1 16 / 107

85.5

学科:ONCOLOGY SCIE Q1 68 / 333

79.73

学科:RESPIRATORY SYSTEM SCIE Q1 21 / 107

80.84

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 85 / 328

74.2

学科:RESPIRATORY SYSTEM SCIE Q1 19 / 108

82.9

学科:ONCOLOGY SCIE Q1 69 / 328

79.12

学科:RESPIRATORY SYSTEM SCIE Q1 23 / 108

79.17


中国学者近期发文

1
First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistanc

Author:Lin, Jia-Xin; Yin, Kai; Yan, Li-Xu; Zhu, Yue; Xu, Bing-Fei; Sun, Yue-Li; Wu, Yi-Long; Tu, Hai-Yan

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.108912

2
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic center

Author:Zhai, Wenyu; Liang, Dachuan; Yu, Xiangyang; Dai, Shuqin; Guo, Xiaotong; Zhou, Yuheng; Yan, Qihang; Li, Liang; Yang, Jie; Wong, Wingshing; Gong, Li; Duan, Fangfang; Li, Xiaodong; Wang, Junye

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109409

3
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA tria

Author:Barlesi, Fabrice; Ahn, Jin Seok; Solomon, Benjamin J.; Nishio, Makoto; Dziadziuszko, Rafal; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Xu, Tingting; Bara, Ilze; Ding, Beiying; Ngiam, Celina; Petric, Patricia; Wu, Yi-Long

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109385

4
Molecular subtyping of small-cell lung cancer in clinical practice: Primary tumor-lymph node concordance, intratumoral heterogeneity, and genomic context in a Chinese cohor

Author:Lin, Zhihong; Lyu, Qiong; Li, Jiawei; Fan, Lei; Wang, Ping; Wu, Yue; Lin, Xiaodong; He, Ping

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109377

5
Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective stud

Author:Huang, Yan; Lin, Xirui; Li, Zhichao; Fang, Caiyan; Chen, Jiyang; Xie, Xiuying; Wu, Hansheng; Wang, Weidong; Yang, Hong; Fu, Jianhua

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109380

6
Risk stratification in stage I invasive non-mucinous lung adenocarcinoma based on high-risk histopathologic feature

Author:Wang, Kai; Ding, Yun; Wang, Zixiao; Zhao, Yifan; Jiang, Yuhang; Mu, Qiuqiao; Gao, Guozheng; Wang, Jing; Zhang, Han; Li, Xin; Sun, Daqiang

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109388

7
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cance

Author:Lin, Jun-Tao; Yang, Xue-Ning; Li, Xiang-Meng; Zhang, Chao; Nie, Qiang; Dong, Song; Jiang, Ben-Yuan; Liao, Ri-Qiang; Kang, Jing; Zhang, Jia-Tao; Yang, Jie; Zhang, Sheng; Hou, Jing-Yu; Fu, Rui; Chen, Zi-Hao; Qiu, Zhen-Bin; Yan, Hong-Hong; Wu, Yi-Long; Zhong, Wen-Zhao

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109389

8
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohor

Author:Dong, Xiaorong; Jian, Hong; Huang, Meijuan; Yuan, Shuanghu; Zhu, Zhengfei; Wu, Lin; Chen, Ming; Bi, Nan; Pan, Yi; Wang, Yingyi; Lv, Dongqing; Monterroso, Elena Armenteros; Huang, Xiangning; Mao, Rui; Fu, Wei; Zhao, Yi; Lu, Shun

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109343

9
18F-FDG PET/CT and receptor-positive circulating tumor cells-based machine learning model for predicting poorly differentiated lung adenocarcinom

Author:Li, Yi; Zhang, Feng-Xian; Zhang, Wen-Long; Shen, Meng-Jun; Yi, Jia-Wei; Zhao, Qing-Qing; Zhao, Qing-Ping; Hao, Li-Yan; Qi, Jia-Jia; Li, Wan-Hu; Wu, Xiao-Dong; Zhao, Long; Wang, Yin

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109353

10
Hypermethylation of SHOX2 and RASSF1A in intraoperative pleural lavage fluid as a molecular signature of aggressive tumor biology and high histologic grade in stage I lung adenocarcinom

Author:Zhang, Yufei; Chen, Liang; Dai, Wenjun; Zhou, Yahui; Shi, Jianxin; Xu, Ye; Zhou, Wenyong

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109357


在线咨询

Lung Cancer

国际简称:LUNG CANCER参考译名:肺癌

年发文量:320 CiteScore:7.4 是否预警:否 Gold OA文章占比:30.75% 研究类文章占比:91.88%

杂志社联系方式:ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, IRELAND, 00000

Lung Cancer